ABSTRACT
Background: Acute gastrointestinal bleeding (GIB) poses a significant challenge in clinical management due to its associated morbidity and mortality. Tranexamic acid (TXA) has emerged as a potential therapeutic agent in controlling hemorrhage by inhibiting fibrinolysis. However, its efficacy in managing acute GIB remains uncertain, necessitating further investigation.
Aim: This prospective medical trial intended to evaluate efficacy of tranexamic acid in managing acute gastrointestinal bleeding by assessing its impact on bleeding control, transfusion requirements, and clinical outcomes.
Methods: A total of 100 patients presenting with acute gastrointestinal bleeding were enrolled in this research. Patients were randomly allotted to receive either tranexamic acid or placebo in addition to standard treatment. The primary endpoint was the rate of bleeding cessation within 24 hours of intervention. Secondary endpoints included transfusion requirements, rebleeding rates, length of hospital stay, and mortality.
Results: The administration of tranexamic acid resulted in a higher rate of bleeding cessation compared to placebo (p < 0.05). Patients receiving tranexamic acid also exhibited reduced transfusion requirements and a lower incidence of rebleeding. Furthermore, the length of hospital stay was meaningly shorter in tranexamic acid group. There were no substantial changes in mortality among two groups.
Conclusion: This prospective clinical trial demonstrates efficiency of tranexamic acid in managing acute gastrointestinal bleeding. The adjunctive use of tranexamic acid contributes to improved bleeding control, reduced transfusion requirements, and shorter hospital stays, without an increased risk of mortality. These findings support the incorporation of tranexamic acid into the standard management protocol for acute gastrointestinal bleeding.
Keywords: Tranexamic acid, acute gastrointestinal bleeding, hemorrhage, clinical trial, bleeding cessation, transfusion requirements, rebleeding, mortality.